Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater, Peter R. Galle, Shahid A. Khan, et al.
Journal of Hepatology (2014) Vol. 60, Iss. 6, pp. 1268-1289
Open Access | Times Cited: 1333

Showing 26-50 of 1333 citing articles:

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini, Daniela Sia, Nabeel Bardeesy, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 2, pp. 291-300
Closed Access | Times Cited: 218
Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma
Bertrand Le Roy, Maximiliano Gelli, Gabriella Pittau, et al.
British journal of surgery (2017) Vol. 105, Iss. 7, pp. 839-847
Closed Access | Times Cited: 218
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Laura Izquierdo‐Sánchez, Ángela Lamarca, Adelaida La Casta, et al.
Journal of Hepatology (2022) Vol. 76, Iss. 5, pp. 1109-1121
Open Access | Times Cited: 218
Update on the Diagnosis and Treatment of Cholangiocarcinoma
Bryan Doherty, Vinod E. Nambudiri, William C. Palmer
Current Gastroenterology Reports (2017) Vol. 19, Iss. 1
Closed Access | Times Cited: 208
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Alexander Stein, Dirk Arnold, John Bridgewater, et al.
BMC Cancer (2015) Vol. 15, Iss. 1
Open Access | Times Cited: 207
YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors
Patricia Marti, Claudia Stein, Tanja Blumer, et al.
Hepatology (2015) Vol. 62, Iss. 5, pp. 1497-1510
Closed Access | Times Cited: 201
EASL Clinical Practice Guidelines on sclerosing cholangitis
Olivier Chazouillères, Ulrich Beuers, Annika Bergquist, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 761-806
Closed Access | Times Cited: 196
Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes
Gu‐Wei Ji, Yu‐Dong Zhang, Hui Zhang, et al.
Radiology (2018) Vol. 290, Iss. 1, pp. 90-98
Closed Access | Times Cited: 185
Cholangiocarcinoma
Adeel S. Khan, Leigh Anne Dageforde
Surgical Clinics of North America (2019) Vol. 99, Iss. 2, pp. 315-335
Closed Access | Times Cited: 176
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription
Qinjunjie Chen, Haibo Wang, Zheng Li, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 135-147
Open Access | Times Cited: 172
Combined hepatocellular-cholangiocarcinoma: An update
Aurélie Beaufrère, Julien Caldéraro, Valérie Paradis
Journal of Hepatology (2021) Vol. 74, Iss. 5, pp. 1212-1224
Open Access | Times Cited: 148
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 137
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 132
Cholangiocarcinoma
Samantha Sarcognato, Diana Sacchi, Matteo Fassan, et al.
Pathologica (2021) Vol. 113, Iss. 3, pp. 158-169
Open Access | Times Cited: 125
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Krämer, Tilmann Bochtler, Chantal Pauli, et al.
Annals of Oncology (2022) Vol. 34, Iss. 3, pp. 228-246
Open Access | Times Cited: 112
Current epidemiology of cholangiocarcinoma in Western countries
Mathew Vithayathil, Shahid A. Khan
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1690-1698
Closed Access | Times Cited: 106
Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression
Chu‐Bin Luo, Haoyang Xin, Zheng‐Jun Zhou, et al.
Hepatology (2022) Vol. 76, Iss. 4, pp. 982-999
Closed Access | Times Cited: 73
Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma
Lucas M. Boehm, Thejus Jayakrishnan, John T. Miura, et al.
Journal of Surgical Oncology (2014) Vol. 111, Iss. 2, pp. 213-220
Open Access | Times Cited: 171
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone
Ioannis T. Konstantinidis, Bas Groot Koerkamp, Richard Kinh Gian, et al.
Cancer (2015) Vol. 122, Iss. 5, pp. 758-765
Open Access | Times Cited: 170
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne, Jérémy Augustin, Anaïs Pujals, et al.
Oncotarget (2017) Vol. 8, Iss. 15, pp. 24644-24651
Open Access | Times Cited: 164
Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan
Yoshihiro Sakamoto, Norihiro Kokudo, Yutaka Matsuyama, et al.
Cancer (2015) Vol. 122, Iss. 1, pp. 61-70
Open Access | Times Cited: 159
The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma
Gaya Spolverato, Mohammad Yawar Yakoob, Yuhree Kim, et al.
Annals of Surgical Oncology (2015) Vol. 22, Iss. 12, pp. 4020-4028
Closed Access | Times Cited: 158
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Jesús M. Bañales, Mercedes Iñarrairaegui, Ander Arbelaiz, et al.
Hepatology (2018) Vol. 70, Iss. 2, pp. 547-562
Open Access | Times Cited: 157
Intrahepatic cholangiocarcinoma: current perspectives
Stefan Buettner, Jeroen L.A. van Vugt, J. IJzermans, et al.
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 1131-1142
Open Access | Times Cited: 149
Cancer review: Cholangiocarcinoma
Boris Blechacz, Yezaz A. Ghouri, Idrees Mian
Journal of Carcinogenesis (2015) Vol. 14, Iss. 1, pp. 1-1
Open Access | Times Cited: 148

Scroll to top